Zoster vaccine: current status and future prospects
- PMID: 20550454
- DOI: 10.1086/653605
Zoster vaccine: current status and future prospects
Abstract
Live, attenuated Oka/Merck varicella-zoster virus (VZV) vaccine (zoster vaccine) protects immunocompetent adults from herpes zoster and its complications. Success of zoster vaccine in preventing the clinical manifestations of latent VZV reactivation contrasts with the failure to achieve similar results with vaccination to prevent recurrent herpes simplex. This reflects major differences in the pathophysiology of latency and reactivation of these 2 alphaherpesviruses. The Shingles Prevention Study and many others have demonstrated that VZV-specific cell-mediated immunity, but not VZV antibody, plays a critical role in limiting reactivation and replication of latent VZV and, thus, in preventing herpes zoster and its complications. Consequently, induction of VZV-specific cell-mediated immunity and not antibody should be used as a proxy for the clinical efficacy of new formulations and uses of zoster vaccine. Prospects for improved zoster vaccines and their use in immunocompromised patients are discussed, and questions related to zoster vaccine use are addressed.
Similar articles
-
Prevention of shingles by varicella zoster virus vaccination.Expert Rev Vaccines. 2006 Aug;5(4):431-43. doi: 10.1586/14760584.5.4.431. Expert Rev Vaccines. 2006. PMID: 16989624 Review.
-
Immune senescence and vaccines to prevent herpes zoster in older persons.Curr Opin Immunol. 2012 Aug;24(4):494-500. doi: 10.1016/j.coi.2012.06.002. Epub 2012 Aug 2. Curr Opin Immunol. 2012. PMID: 22857823 Review.
-
Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.J Virol. 2018 Jun 29;92(14):e00269-18. doi: 10.1128/JVI.00269-18. Print 2018 Jul 15. J Virol. 2018. PMID: 29743372 Free PMC article.
-
A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.J Drugs Dermatol. 2006 Oct;5(9):863-6. J Drugs Dermatol. 2006. PMID: 17039651 Review.
-
T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine.J Immunol. 1989 Jan 15;142(2):636-41. J Immunol. 1989. PMID: 2536059
Cited by
-
Vaccines for the Elderly and Vaccination Programs in Europe and the United States.Vaccines (Basel). 2024 May 22;12(6):566. doi: 10.3390/vaccines12060566. Vaccines (Basel). 2024. PMID: 38932295 Free PMC article. Review.
-
Progress in VZV vaccination? Some concerns.Med Microbiol Immunol. 2013 Aug;202(4):257-8. doi: 10.1007/s00430-013-0298-x. Epub 2013 May 7. Med Microbiol Immunol. 2013. PMID: 23649706 Review.
-
Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.Pediatr Infect Dis J. 2013 Nov;32 Suppl 2(0 2):i-KK4. doi: 10.1097/01.inf.0000437856.09540.11. Pediatr Infect Dis J. 2013. PMID: 24569199 Free PMC article. No abstract available.
-
Global aspects of viral glycosylation.Glycobiology. 2018 Jul 1;28(7):443-467. doi: 10.1093/glycob/cwy021. Glycobiology. 2018. PMID: 29579213 Free PMC article.
-
Current status and prospects for development of an HSV vaccine.Vaccine. 2014 Mar 20;32(14):1553-60. doi: 10.1016/j.vaccine.2013.08.066. Epub 2013 Sep 6. Vaccine. 2014. PMID: 24016811 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
